NSE: COHANCE | BSE: 543064

Expensive Underperformer

Download real time

569.80 0.00 (0.00%)

New 52W Low in past week

1,136 NSE Volume

NSE 25 Nov, 2025 9:07 AM (IST)

21,798.7

Market Cap

High in industry

0.6

Beta 1Year

Very Low volatility

Cohance Lifesciences Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for COHANCE, BSE:543064 Cohance Lifesciences Ltd.

Cohance Lifesciences Ltd.

25 Sep 2020, 12:00AM

Suven Pharmaceuticals

Hold: Cohance Lifesciences Ltd.

ICICI Securities Limited

Suven Pharma has turned ex-bonus from September 25, 2020 pursuant to the board approval granted for the issue of bonus shares in its meeting held on September 16, 2020. The record date for the same has been fixed as September 28, 2020. The board has recommended the issue of bonus shares in proportion of one bonus share (face value of | 1 each) for every equity share held (i.e. 1:1). Consequently, the share price has changed to | 369/share from | 738/share. Accordingly, our target price has also been revised to | 385/share from | 770/share earlier. After the recent run up, the...

ICICI Securities Limited downgraded Cohance Lifesciences Ltd. to Sell with a price target of 640.0 on 13 Nov, 2025.

Cohance Lifesciences Ltd.

20 Aug 2020

SUVEN PHARMACEUTICALS LIMITED

Accumulate: Cohance Lifesciences Ltd.

Recommendation Target

Geojit BNP Paribas

We downgrade our rating from Buy to Accumulate, based on 22x FY22E EPS with a target price of Rs.746 as the recent rally has factored in the positive triggers for the company . SPL's Q1FY21 revenue grew by 21% YoY to Rs.238cr led by growth...

Cohance Lifesciences Ltd. has lost -47.66% in the last 6 Months

Cohance Lifesciences Ltd.

19 Aug 2020

Suven Pharmaceuticals

Buy: Cohance Lifesciences Ltd.

ICICI Securities Limited

Post de-merger from Suven Life Sciences, pharma business will be largely driven by two cash cow CRAMS segments i.e. pharma, speciality chemicals. With a strong margin profile (+40%) without the R&D; burden of innovative pipeline, the free cash flow is likely to remain strong. Despite pandemic and high base, the company has guided 10-15% growth based on strong order book position (albeit some expected delays). Despite significant run up, there is still scope for upside as the company is still trading at significant discount to some leading players in the space dealing with innovators. We...

Promoters have decreased holdings from 66.41% to 57.49% in Sep 2025 qtr

Cohance Lifesciences Ltd.

18 Aug 2020

Suven Pharma

Buy: Cohance Lifesciences Ltd.

Anand Rathi

Valuation. At the CMP of `652, the stock trades at 22.1x, 18.3x and 15.5x respective FY21e/22e/23e earnings. We retain our Buy recommendation, with a higher price target of `760 (earlier `695), based on 18x FY23e EPS. Risks:...

Number of FII/FPI investors decreased from 214 to 206 in Sep 2025 qtr

Cohance Lifesciences Ltd.

02 Jul 2020

SUVEN PHARMACEUTICALS LIMITED

Buy: Cohance Lifesciences Ltd.

Geojit BNP Paribas

During the year total revenues grew by 27% to Rs.834crs driven by 18% growth in CRAMS, 41% growth in Speciality chemicals and 40% growth in Formulations. In the CRAMS segment, the company has been able to add new customers during the year and the segment is now 56% of total revenues. In the coming year, the management stated that new projects may be difficult to undertake owing to the ongoing Covid-19 scenario. In CRAMS, the company plans to integrate into APIs and later into formulations, in addition to intermediates, which it is currently focusing on. We expect a revenue CAGR of 13% for CRAMS over FY20-FY22E...

Cohance Lifesciences Ltd. has lost -34.98% in the last 1 Month

VOTE: Is Suven Pharmaceuticals Ltd. worth buying?

30 Votes:

Buy 66.67%

Sell 16.67%

Hold 16.67%

RESEARCH REPORTS

Sell SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf